The results indicated that the levels of expression of both SREBP-1 and SCAP in the NSCLC samples were higher than those in the non-tumor samples, and that these elevated levels were stage-dependent (Figure 1C,D). This evidence concerns the gene SCAP and non-small cell lung carcinoma.